Principal Investigator
David Kerman
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230197
Clinical Trial Summary
AGMB-129-C102: A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohns Disease.
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Niurka Colina
Phone Number
+1 (305) 2436405
Email
nxc610@miami.edu